Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84

Bone

Volumn 44, Issue 1, 2009, Pages 113-119

  Recker, R R ^a   Bare, S P ^a   Smith, S Y ^b   Varela, A ^b   Miller, M A ^c   Morris, S A ^c   Fox, J ^c  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

^c NPS Pharmaceuticals   (United States)

Author keywords

Bone formation; Bone remodeling; Bone structure; Osteoporosis; Parathyroid hormone

Indexed keywords

CALCIUM; COLECALCIFEROL; PARATHYROID HORMONE; PLACEBO; TETRACYCLINE;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE MINERAL; BONE REMODELING; BONE STRUCTURE; CANCELLOUS BONE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICAL BONE; DOUBLE BLIND PROCEDURE; DRUG SELF ADMINISTRATION; FEMALE; HIP; HUMAN; ILIAC CREST; IMAGING SYSTEM; LUMBAR SPINE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MULTICENTER STUDY; OSSIFICATION; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT RESPONSE;

BIOPSY; BONE DENSITY; BONE REMODELING; BONE RESORPTION; DEMOGRAPHY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ILIUM; MIDDLE AGED; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PERIOSTEUM; PLACEBOS; STAINING AND LABELING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 57449090596     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.09.019     Document Type: Article

References (29)

1. Reeve J., Meunier P.J., Parsons J.A., Bernat M., Bijvoet O.L., Courpron P., et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br. Med. J. 280 (1980) 1340-1344
2. Fox J. Developments in parathyroid hormone and related peptides as bone-formation agents. Curr. Opin. Pharmacol. 2 (2002) 338-344
3. Hodsman A.B., Bauer D.C., Dempster D.W., Dian L., Hanley D.A., Harris S.T., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr. Rev. 26 (2005) 688-703
4. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344 (2001) 1434-1441
5. Greenspan S.L., Bone H.G., Ettinger M.P., Hanley D.A., Lindsay R., Zanchetta J.R., et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med. 146 (2007) 326-339
6. Bradbeer J.N., Arlot M.E., Meunier P.J., and Reeve J. Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin. Endocrinol. (Oxf) 37 (1992) 282-289
7. Hodsman A.B., Kisiel M., Adachi J.D., Fraher L.J., and Watson P.H. Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone 27 (2000) 311-318
8. Dempster D.W., Cosman F., Kurland E.S., Zhou H., Nieves J., Woelfert L., et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J. Bone Miner. Res. 16 (2001) 1846-1853
9. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., and Eriksen E.F. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J. Bone Miner. Res. 18 (2003) 1932-1941
10. Fox J., Miller M.A., Newman M.K., Turner C.H., Recker R.R., and Smith S.Y. Treatment of skeletally-mature ovariectomized rhesus monkeys with parathyroid hormone 1-84 for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J. Bone Miner. Res. 22 (2007) 260-273
11. Fox J., Miller M.A., Recker R.R., Turner C.H., and Smith S.Y. Effects of treatment of ovariectomized adult rhesus monkeys with parathyroid hormone 1-84 for 16 months on trabecular and cortical bone structure and biomechanical properties of the proximal femur. Calcif. Tissue Int. 81 (2007) 53-63
12. Hildebrand T., and Ruegsegger P. Quantification of bone microarchitecture with the structure model index. Comput. Methods Biomech. Biomed. Eng. 1 (1997) 15-23
13. Hildebrand T., Laib A., Muller R., Dequeker J., and Ruegsegger P. Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J. Bone Miner. Res. 14 (1999) 1167-1174
14. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2 (1987) 595-610
15. Marcus R., Wang O., Satterwhite J., and Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J. Bone Miner. Res. 18 (2003) 18-23
16. Parisien M.V., McMahon D., Pushparaj N., and Dempster D.W. Trabecular architecture in iliac crest bone biopsies: intra-individual variability in structural parameters and changes with age. Bone 9 (1988) 289-295
17. Black D.M., Bilezikian J.P., Ensrud K.E., Greenspan S.L., Palermo L., Hue T., et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N. Engl. J. Med. 353 (2005) 555-565
18. Fox J., Newman M.K., Turner C.H., Guldberg R.E., Varela A., and Smith S.Y. Effects of treatment with parathyroid hormone 1-84 on quantity and biomechanical properties of thoracic vertebral trabecular bone in ovariectomized rhesus monkeys. Calcif. Tissue Int. 82 (2008) 212-220
19. Miller M.A., Bare S.P., Recker R.R., Smith S.Y., and Fox J. Intratrabecular tunneling increases trabecular number throughout the skeleton of ovariectomized rhesus monkeys treated with parathyroid hormone 1-84. Bone 42 (2008) 1175-1183
20. Greenspan S.L., Hanley D.A., Morris S., and Marriott T.B. Bone turnover markers and BMD remain elevated in postmenopausal osteoporotic women through a full 24 months of treatment with human parathyroid hormone 1-84 (PTH). J. Bone Miner. Res. 21 Suppl. 1 (2006) S114
21. Dobnig H., Sipos A., Jiang Y., Fahrleitner-Pammer A., Ste-Marie L.G., Gallagher J.C., et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J. Clin. Endocrinol. Metab. 90 (2005) 3970-3977
22. Lindsay R., Zhou H., Cosman F., Nieves J., Dempster D.W., and Hodsman A.B. Effects of one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J. Bone Miner. Res. 22 (2007) 495-502
23. Fox J., Miller M.A., Newman M.K., Recker R.R., Turner C.H., and Smith S.Y. Effects of daily treatment with parathyroid hormone 1-84 on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Bone 41 (2007) 321-330
24. Bogado C.E., Lang T.F., Zanchetta J.R., Mango A., Koyama A., Mathisen A.L., et al. Longitudinal changes in trabecular and cortical BMD and indices of bone strength assessed by quantitative computed tomography at the hip of postmenopausal osteoporotic women treated with parathyroid hormone (1-84) for 18 months. J. Bone Miner. Res. 21 Suppl 1 (2006) S296
25. Burr D.B., Hirano T., Turner C.H., Hotchkiss C., Brommage R., and Hock J.M. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J. Bone Miner. Res. 16 (2001) 157-165
26. Sato M., Westmore M., Ma Y.L., Schmidt A., Zeng Q.Q., Glass E.V., et al. Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J. Bone Miner. Res. 19 (2004) 623-629
27. Jerome C.P., Burr D.B., Van Bibber T., Hock J.M., and Brommage R. Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fasicularis). Bone 28 (2001) 150-159
28. Hodsman A.B., Hanley D.A., Ettinger M.P., Bolognese M.A., Fox J., Metcalfe A.J., et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 88 (2003) 5212-5220
29. Lindsay R., Scheele W.H., Neer R., Pohl G., Adami S., Mautalen C., et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch. Intern. Med. 164 (2004) 2024-2030